LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Actinium Pharmaceuticals Inc

Fechado

1.81 8.38

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.62

Máximo

1.84

Indicadores-chave

By Trading Economics

Rendimento

-9.3M

-16M

EPS

-0.51

Funcionários

31

EBITDA

-9.3M

-17M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+255.03% upside

Dividendos

By Dow Jones

Próximos Ganhos

1 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

2.2M

51M

Abertura anterior

-6.57

Fecho anterior

1.81

Actinium Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jun. de 2025, 20:45 UTC

Ganhos

Broadcom 2Q Sales Climb on Booming AI Demand

5 de jun. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 de jun. de 2025, 23:44 UTC

Conversa de Mercado

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 de jun. de 2025, 23:30 UTC

Conversa de Mercado

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 de jun. de 2025, 21:32 UTC

Ganhos

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

5 de jun. de 2025, 20:45 UTC

Ganhos

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 de jun. de 2025, 20:24 UTC

Ganhos

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Rev $15B >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Net $4.97B >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Adj EPS $1.58 >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q EPS $1.03 >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom Sees 3Q Rev $15.8B >AVGO

5 de jun. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 de jun. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 de jun. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 de jun. de 2025, 19:22 UTC

Conversa de Mercado

Oil Futures Resume Upward Moves -- Market Talk

5 de jun. de 2025, 19:00 UTC

Conversa de Mercado

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 de jun. de 2025, 18:32 UTC

Conversa de Mercado

Gold Slips After Trump-Xi Call -- Market Talk

5 de jun. de 2025, 18:26 UTC

Ganhos

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 de jun. de 2025, 18:06 UTC

Conversa de Mercado

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 de jun. de 2025, 16:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

5 de jun. de 2025, 16:18 UTC

Conversa de Mercado

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2025, 16:12 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

5 de jun. de 2025, 16:12 UTC

Conversa de Mercado

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 de jun. de 2025, 16:03 UTC

Conversa de Mercado

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 de jun. de 2025, 15:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Actinium Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

255.03% parte superior

Previsão para 12 meses

Média 6 USD  255.03%

Máximo 9 USD

Mínimo 4 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Actinium Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.